RECOCEPT TZ INJ

Ceftriaxon 1 gm,Tazobactum 125 mg Injection.

Ceftriaxone 

ceftriaxone Injection is an antibacterial drug used to treat conditions such as lower respiratory tract infections, skin and skin structure infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, and meningitis.

Tazobactam

Tazobactam is a beta-lactamase inhibitor used for the treatment of infections caused by susceptible bacteria. This medicine is used in combination with other beta-lactam antibiotics, usually when more commonly used systemic antibiotics may be ineffective due to bacterial resistance.

 

SIDE EFFECTS OF CEFTRIAXONE 1000MG + TAZOBACTAM 125MG:

SUPERINFECTION; ANAPHYLAXIS; DIARRHOEA; LOCAL REACTIONS; BLOOD DYSCRASIAS; RASH, FEVER, PRURITUS; ELEVATED TRANSAMINASES AND ALKALINE PHOSPHATASE. GI EFFECTS; PSEUDOMEMBRANOUS COLITIS; HEMATOLOGIC EFFECTS; HYPERSENSITIVITY REACTIONS; CNS DISTURBANCES; HYPERTENSION; CHEST PAIN; EDEMA; MONILIASIS; RHINITIS; DYSPNEA; HYPOTENSION; ILEUS; SYNCOPE; LOCAL INJ SITE REACTIONS; RIGORS. POTENTIALLY FATAL: PSEUDOMEMBRANOUS COLITIS; NEPHROTOXICITY.

DRUG INTERACTIONS OF CEFTRIAXONE 1000MG + TAZOBACTAM 125MG:

PROBENECID; AMINOGLYCOSIDES; VECURONIUM, METHOTREXATE; ORAL ANTICOAGULANTS; HEPARIN. POTENTIALLY FATAL: DISULFIRAM-LIKE REACTION WITH ALCOHOL. NEPHROTOXICITY WITH AMINOGLYCOSIDES AND FUROSEMIDE.

CONTRAINDICATIONS OF CEFTRIAXONE 1000MG + TAZOBACTAM 125MG:

HYPERSENSITIVITY TO CEPHALOSPORINS AND Β-LACTAMASE INHIBITORS.

MECHANISM OF ACTION OF CEFTRIAXONE 1000MG + TAZOBACTAM 125MG:

CEFTRIAXONE INTERFERES WITH THE BIOSYNTHESIS OF THE PEPTIDOGLYCAN COMPONENT OF THE BACTERIAL CELL WAY BY BINDING TO AND INACTIVATING PENICLLIN-BINDING PROTEINS (PBPS). TAZOBACTAM IS A PENICILLANIC ACID SULFONE DERIVATIVE WITH Β-LACTAMASE INHIBITORY PROPERTIES. IT ENHANCES THE ACTIVITY OF Β-LACTAM ANTIBACTERIALS AGAINST Β-LACTAMASE-PRODUCING BACTERIA. DISTRIBUTION: CEFTRIAXONE: 98% BOUND TO PLASMA PROTEINS; CROSSES THE BLOOD BRAIN BARRIER. TAZOBACTAM: ABOUT 30% BOUND TO PLASMA PROTEINS; WIDELY DISTRIBUTED TO TISSUES AND BODY FLUIDS. EXCRETION: CEFTRIAXONE: ELIMINATION HALF-LIFE IS ABOUT 8.7 HR; 33-67% REMOVED AS UNCHANGED DRUG. TAZOBACTAM: REMOVED MAINLY VIA KIDNEYS WITH 80% OF AN ADMINISTERED DOSE AS UNCHANGED DRUG.

SPECIAL PRECAUTIONS FOR CEFTRIAXONE 1000MG + TAZOBACTAM 125MG:

HISTORY OF PENICILLIN ALLERGY; LACTATION. CONSIDER POSSIBILITY OF PSEUDOMEMBRANOUS COLITIS IN PATIENTS WHO PRESENT WITH DIARRHOEA SUBSEQUENT TO THE ADMIN OF ANTIBACTERIAL AGENTS. MONITOR PROTHROMBIN TIME IN PATIENTS WITH IMPAIRED VIT K SYNTHESIS OR LOW VIT K STORES DURING TREATMENT. PROLONGED TREATMENT MAY RESULT IN OVERGROWTH OF NONSUSCEPTIBLE ORGANISMS. CAUTION IN PATIENTS WITH A HISTORY OF GI DISEASE, ESPECIALLY COLITIS. DISCONTINUE TREATMENT IN PATIENTS WHO DEVELOP SIGNS/SYMPTOMS SUGGESTIVE OF GALLBLADDER DISEASE. NOT TO BE USED IN HYPERBILIRUBINEMIC NEONATES, ESPECIALLY PREMATURES.

Packaging:

1.250 Gram Pack With W.F.I With Mono Carton.

 

For Use of Registered Medical Practitioner or a Hospital Only.